Clinical and radiographic evaluation of pulpotomies employing calcium hydroxide and trioxide mineral aggregate.
This study utilized clinical and radiographic examinations to compare the effectiveness of calcium hydroxide paste and mineral trioxide aggregate (MTA) for pulpotomies of primary molars in children. Ninety primary molars that showed clinical and radiographic indications for pulpotomy treatment were selected. The pulpotomies were performed in two sessions, using a corticosteroid/antibiotic solution as therapeutic dressing. The sample was divided into two groups of 45 teeth, in which the pulpal remains were protected with either calcium hydroxide paste (Group 1) or MTA (Group 2). Radiographs were taken immediately and at 3-, 6-, and 12-month follow-up appointments. Three teeth in Group 1 failed after three months, while two cases failed after six months and one more failed at one year. Two failures were found in Group 2 at the 12-month follow-up. These results indicate that both materials may be utilized for pulpotomies in primary teeth.
Percinoto
Celio
C
Department of Social and Pediatric Dentistry, School of Dentistry of Aracatuba, Paulista State University (UNESP), Sao Paulo, Brazil.
de Castro
Alessandra Maia
AM
Pinto
Leila Maria Cesario Pereira
LM
D017607:Aluminum Compounds / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use*; D002126:Calcium Hydroxide / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003188:Composite Resins; D003782:Dental Pulp / Q000000981:diagnostic imaging / Q000187:drug effects; D003785:Dental Pulp Capping / Q000379:methods*; D003793:Dental Restoration, Permanent; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005899:Glass Ionomer Cements / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D008903:Minerals / Q000627:therapeutic use; D008963:Molar / Q000000981:diagnostic imaging / Q000473:pathology; D009355:Neomycin / Q000627:therapeutic use; D010087:Oxides / Q000627:therapeutic use*; D011112:Polymyxin B / Q000627:therapeutic use; D011672:Pulpotomy / Q000379:methods*; D011859:Radiography; D012387:Root Canal Filling Materials / Q000627:therapeutic use; D017640:Silicates / Q000627:therapeutic use*; D014094:Tooth, Deciduous / Q000000981:diagnostic imaging / Q000473:pathology; D016896:Treatment Outcome
D017607:Aluminum Compounds; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D017610:Calcium Compounds; D003188:Composite Resins; D004338:Drug Combinations; D005899:Glass Ionomer Cements; D008903:Minerals; D010087:Oxides; D012387:Root Canal Filling Materials; D017640:Silicates; C467914:TPH spectrum; C033225:hydrocortisone, neomycin, polymyxin B drug combination; C086631:mineral trioxide aggregate; C067790:Vitrabond; C025702:Dycal; D009355:Neomycin; D011112:Polymyxin B; D002126:Calcium Hydroxide; D006854:Hydrocortisone